Inhibition of HAT is currently being explored as a new class of cancer treatment, but despite promising results, no HAT inhibitors are currently approved; therefore, the anticancer potential of the HAT inhibition of curcumin has not been explored as much as its HDAC inhibition activity [8]. Here, TMPRSS11D is linked to cancer.